Venous Thromboembolism Taskforce Audit Program - Full Text View

Purpose

To determine the effect of an interventional campaign run by a dedicated "VTE Nurse Educator" over a 6-month period and the effect on prophylaxis rates.

To determine the proportion of medically admitted patients with risk factors for VTE.

To assess and compare the use of venous thromboembolism (VTE) prophylaxis in hospitalized medical patients versus recommendations and current guidelines.

To determine the patient characteristics of those deemed to be at risk of VTE. To determine the proportion of patients receiving appropriate thromboprophylaxis for their risk.

To determine the type and duration (where possible) of prophylaxis used.

Condition

Venous Thrombosis

U.S. FDA Resources

Study Type:	Observational
Study Design:	Case-Only, Prospective

Official Title:	Venous Thromboembolism Taskforce Audit Program

Further study details as provided by Sanofi-Aventis:

Biospecimen Retention: None Retained

Biospecimen Description:

Enrollment:	8764
Study Start Date:	June 2007
Primary Completion Date:	August 2008 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

Venous thromboembolism in medical patients bedridden due to acute illness.

Criteria

Inclusion Criteria:

Hospital admission for an acute illness with an in-patient hospital stay of 3 days or more.

Exclusion Criteria:

Patients who have undergone any type of surgery during current admission
Patients who are admitted to a ward or department that is excluded from this study e.g psychiatric, paediatric, maternity, intensive care unit, coronary care unit.
Prior enrollment in this protocol during current admission
Prior enrollment in a VTE study involving pharmaceutical or mechanical treatment within last 90 days.
Admission for suspected or diagnosed deep vein thrombosis

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00535171

Locations


Australia
	Sanofi-Aventis
	MacQuarie Park, Australia

Sponsors and Collaborators

Sanofi-Aventis

Investigators


Study Director:	Fiona Howard	Sanofi-Aventis

More Information

Responsible Party:	sanofi-aventis ( Medical Affairs Study Director )
Study ID Numbers:	DIREG_L_01927
First Received:	September 25, 2007
Last Updated:	September 9, 2008
ClinicalTrials.gov Identifier:	NCT00535171
Health Authority:	Australia: Department of Health and Ageing Therapeutic Goods Administration

Study placed in the following topic categories:

Embolism and Thrombosis

Embolism

Vascular Diseases

Venous Thrombosis

Venous Thromboembolism

Thromboembolism

Thrombosis

Additional relevant MeSH terms:

Cardiovascular Diseases

ClinicalTrials.gov processed this record on October 03, 2008

Sponsored by:	Sanofi-Aventis
Information provided by:	Sanofi-Aventis
ClinicalTrials.gov Identifier:	NCT00535171